As BioNTech progresses with its goal to grow into a “fully integrated immunotherapy powerhouse,” the German biotech is e | ...

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $143.00. Discover outperforming ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on BioNTech SE (BNTX – Research Report). The company’s shares closed yesterday at $104.68.